Published in Am J Neurodegener Dis on September 18, 2013
Analysis of the advantage features of Beijing surveillance network for Creutzfeldt-Jakob disease. Prion (2015) 0.84
The 37/67kDa laminin receptor (LR) inhibitor, NSC47924, affects 37/67kDa LR cell surface localization and interaction with the cellular prion protein. Sci Rep (2016) 0.77
Transgenic over-expression of mammalian heparanase delays prion disease onset and progression. Biochem Biophys Res Commun (2015) 0.76
Prion diseases: immunotargets and therapy. Immunotargets Ther (2016) 0.75
Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis (2016) 0.75
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Sustained translational repression by eIF2α-P mediates prion neurodegeneration. Nature (2012) 3.54
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A (2001) 3.39
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology (2012) 2.66
Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem (2010) 2.57
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol (2009) 2.41
Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature (1992) 2.11
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol (2004) 1.97
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology (2004) 1.82
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev (2006) 1.50
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci (2012) 1.50
Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem (2009) 1.50
Birth of a prion: spontaneous generation revisited. Cell (2005) 1.42
Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol (1987) 1.39
Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst (2008) 1.39
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord (2004) 1.27
The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis (2006) 1.20
Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J Virol (1997) 1.14
Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem (2006) 1.13
Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci U S A (2004) 1.10
Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol (2000) 1.09
Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol (2004) 1.07
Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology (2009) 1.03
Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol (2005) 1.03
Recent advances in prion chemotherapeutics. Infect Disord Drug Targets (2009) 1.03
Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. J Biol Chem (2008) 1.01
Rapidly progressive dementias and the treatment of human prion diseases. Expert Opin Pharmacother (2010) 1.00
[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation]. Rinsho Shinkeigaku (2003) 0.98
A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains. Proc Natl Acad Sci U S A (2008) 0.98
The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One (2008) 0.96
Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry (2007) 0.95
p53-Dependent transcriptional control of cellular prion by presenilins. J Neurosci (2009) 0.94
LRP/LR as an alternative promising target in therapy of prion diseases, Alzheimer's disease and cancer. Infect Disord Drug Targets (2009) 0.94
Development of antibody fragments for immunotherapy of prion diseases. Biochem J (2009) 0.92
Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells. J Biol Chem (2009) 0.92
Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis (1992) 0.91
Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol (2004) 0.90
Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord (2013) 0.89
Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol (2005) 0.88
A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion disease. Free Radic Biol Med (2008) 0.87
Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate. Acta Neurol Scand (2009) 0.87
[Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings]. Arq Neuropsiquiatr (2004) 0.87
Vaccine approaches to prevent and treat prion infection : progress and challenges. BioDrugs (2008) 0.86
[Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine]. Nihon Rinsho (2002) 0.86
Microinjection of lentiviral vectors expressing small interfering RNAs directed against laminin receptor precursor mRNA prolongs the pre-clinical phase in scrapie-infected mice. J Gen Virol (2009) 0.86
Tetracyclines and prion infectivity. Infect Disord Drug Targets (2009) 0.86
Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. Infect Disord Drug Targets (2009) 0.83
The P's and Q's of cellular PrP-Aβ interactions. Prion (2012) 0.83
RNAi for the treatment of prion disease: a window for intervention in neurodegeneration? CNS Neurol Disord Drug Targets (2009) 0.82
Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? Biochemistry (2003) 0.81
Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J Gen Virol (2007) 0.81
Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208. Biochem Biophys Res Commun (2007) 0.80
Knock-down of the 37-kDa/67-kDa laminin receptor in mouse brain by transgenic expression of specific antisense LRP RNA. Transgenic Res (2004) 0.79
Therapy in prion diseases: from molecular and cellular biology to therapeutic targets. Infect Disord Drug Targets (2009) 0.79
Therapeutic approaches targeting the prion receptor LRP/LR. Vet Microbiol (2007) 0.79
Drug-induced Creutzfeldt-Jakob like syndrome. J Psychiatry Neurosci (1992) 0.79
Recent developments in mucosal vaccines against prion diseases. Expert Rev Vaccines (2007) 0.78
Spreading proteins in neurodegeneration: where do they take us? Brain (2013) 0.78
Development of vaccination approaches for the treatment of neurological diseases. J Comp Neurol (2009) 0.78
Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies. Expert Opin Biol Ther (2006) 0.77
Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. ACS Chem Neurosci (2013) 0.77
[Therapeutics for prion diseases]. Rinsho Shinkeigaku (2003) 0.76
Progress in prion vaccines and immunotherapies. Expert Opin Biol Ther (2005) 0.76
Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters. J Mol Neurosci (2002) 0.76
Recent progress in prion and prion-like protein aggregation. Acta Biochim Biophys Sin (Shanghai) (2013) 0.76
An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Anal Biochem (2004) 0.76
Weight management issues and strategies for people with high cardiovascular risk undertaking an Australian weight loss program: a focus group study. Nurs Health Sci (2012) 0.84
A randomised trial of a weight loss intervention for overweight and obese people diagnosed with coronary heart disease and/or type 2 diabetes. Ann Behav Med (2012) 0.81
Multi-component weight-loss interventions for people with cardiovascular disease and/or type 2 diabetes mellitus: a systematic review. Eur J Cardiovasc Nurs (2013) 0.77
A patient with Creutzfeldt-Jakob disease presenting with amyotrophy: a case report. J Med Case Rep (2013) 0.76
The distress of voice-hearing: the use of simulation for awareness, understanding and communication skill development in undergraduate nursing education. Nurse Educ Pract (2013) 0.75
Participants' perspectives of a multi-component, group-based weight loss programme supplement for cardiac rehabilitation: a qualitative study. Int J Nurs Pract (2012) 0.75